Stock listing

ASX:CBL Control Bionics Ltd. Share Price

Follow Control Bionics Ltd. into a list and get an email when it puts out news.

Share price · ASX:CBL

$0.042 AUD -0.007 (-14.3%)

Close on Nov 20, 2026

Past year -36.4% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$0.042 – $0.044 AUDNov 20, 2026
Volume
1.74M sharesNov 20, 2026
Market cap
$22.85M AUDAt the close on Nov 20, 2026 · price × 544.1M shares outstanding
52-week range
$0.042 – $0.095 AUDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$24,872 AUDMedian day 230,911 shares · 3 days with no trades · last 3 months, Aug 20, 2026 – Nov 20, 2026
Control Bionics Ltd. logo

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · ASX:CBL · AUD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$0.042-0.007-14.3%$0.044$0.044$0.0421,735,745
$0.049+0.001+2.1%$0.048$0.049$0.048177,708
$0.048-0.003-5.9%$0.050$0.050$0.048695,862
$0.051-0.002-3.8%$0.053$0.053$0.051308,541
$0.053-0.001-1.9%$0.053$0.053$0.053358,516
$0.054+0.004+8.0%$0.055$0.055$0.0521,010,254
$0.0500.0000.0%$0.050$0.050$0.05011,000
$0.0500.0000.0%$0.050$0.051$0.049311,970
$0.050+0.001+2.0%$0.052$0.052$0.04896,172
$0.0490.0000.0%$0.049$0.049$0.0495,000
$0.0490.0000.0%$0.049$0.049$0.0495,000
$0.0490.0000.0%$0.049$0.049$0.04929,860
$0.049-0.001-2.0%$0.048$0.050$0.048210,714
$0.050-0.002-3.8%$0.050$0.050$0.050662,057
$0.052+0.003+6.1%$0.050$0.052$0.049240,667
$0.0490.0000.0%$0.050$0.051$0.0491,371,182
$0.049-0.004-7.5%$0.053$0.053$0.0492,278,967
$0.0530.0000.0%$0.053$0.053$0.05387,434
$0.053-0.003-5.4%$0.053$0.053$0.05315,878
$0.056+0.002+3.7%$0.054$0.056$0.053306,352
$0.0540.0000.0%$0.056$0.056$0.054162,373
$0.054-0.002-3.6%$0.056$0.056$0.0531,054,018
$0.056-0.002-3.4%$0.059$0.059$0.0541,058,665
$0.0580.0000.0%$0.058$0.058$0.0580
$0.058-0.002-3.3%$0.060$0.060$0.058130,000
$0.060-0.003-4.8%$0.063$0.063$0.060523,861
$0.063-0.002-3.1%$0.066$0.066$0.063378,219
$0.0650.0000.0%$0.065$0.065$0.06510,000
$0.065+0.002+3.2%$0.066$0.066$0.065517,227
$0.063-0.003-4.5%$0.066$0.066$0.063103,000
$0.066+0.001+1.5%$0.064$0.066$0.063253,785
$0.065+0.001+1.6%$0.066$0.066$0.065400,629
$0.064+0.004+6.7%$0.060$0.064$0.060189,928
$0.060-0.001-1.6%$0.060$0.060$0.060141,590
$0.061-0.001-1.6%$0.062$0.062$0.061204,634
$0.0620.0000.0%$0.062$0.062$0.058493,553
$0.0620.0000.0%$0.062$0.062$0.06210,000
$0.062+0.006+10.7%$0.056$0.062$0.056477,153
$0.056-0.001-1.8%$0.056$0.056$0.056100,000
$0.057-0.001-1.7%$0.056$0.057$0.056413,205
$0.0580.0000.0%$0.058$0.059$0.058421,138
$0.0580.0000.0%$0.058$0.059$0.058221,154
$0.058-0.003-4.9%$0.062$0.062$0.058535,322
$0.061-0.001-1.6%$0.061$0.061$0.0615,000
$0.062+0.002+3.3%$0.061$0.062$0.0615,071
$0.0600.0000.0%$0.060$0.060$0.06021,666
$0.060-0.001-1.6%$0.060$0.060$0.06022,085
$0.0610.0000.0%$0.061$0.061$0.059837,943
$0.0610.0000.0%$0.061$0.061$0.0610
$0.061+0.001+1.7%$0.060$0.061$0.060140,006
$0.0600.0000.0%$0.060$0.060$0.0600
$0.060-0.002-3.2%$0.060$0.060$0.059258,175
$0.062+0.004+6.9%$0.059$0.062$0.059214,999
$0.058-0.001-1.7%$0.058$0.060$0.058367,203
$0.059-0.003-4.8%$0.060$0.060$0.059110,001
$0.062+0.004+6.9%$0.063$0.063$0.06255,552
$0.058-0.003-4.9%$0.060$0.060$0.058334,879
$0.061+0.001+1.7%$0.062$0.062$0.06169,343
$0.060+0.002+3.4%$0.060$0.060$0.06050,944
$0.058-0.002-3.3%$0.058$0.060$0.058745,009
$0.060-0.001-1.6%$0.065$0.065$0.0604,922,270
$0.061+0.002+3.4%$0.060$0.061$0.060145,482
$0.059+0.001+1.7%$0.063$0.063$0.057491,456
$0.058-0.002-3.3%$0.060$0.060$0.058296,570
$0.0600.0000.0%$0.061$0.061$0.059704,803
$0.0600.0000.0%$0.061$0.063$0.0591,810,561
Ticker
ASX:CBL
Asset type
Stock
Sector
Health care
Industry
Medical devices & supplies
Exchange
ASX
Currency
AUD

What changed lately

Latest news

NeuroStrip secures MHRA registration

Aug 24, 2026

Closed $0.059 (+1.7%) on Aug 25, 2026

Completion of Placement

Jun 24, 2026

Closed $0.085 (-2.3%) on Jun 25, 2026

Pause in Trading

Jun 23, 2026

Closed $0.087 (0.0%) on Jun 24, 2026

Commercial Momentum Presentation

Jun 3, 2026

Closed $0.07 (+18.6%) on Jun 4, 2026

All Control Bionics Ltd. news

Control Bionics Ltd. on 6ix

Sector
Health care
Industry
Medical devices & supplies
News releases
17 in the last 12 months · 84 in all · newest Oct 28, 2026 · oldest 2016
Decks
25 decks · latest Nov 18, 2026

Valuation

EV/sales 4.5× against a median of 1.2×: 8th lowest of 9 Medical devices & supplies companies shown. Statements: Year to Dec 31, 2025 · balance Jun 30, 2026 · price Nov 20, 2026

Enterprise value
$21.40M AUD
P/E
Loss
EV/sales
4.5×
EV/EBITDA
Negative EBITDA
Price/book
3.6×
Gross margin
−86.8%
Operating margin
−153.0%
Net margin
−152.4%
Debt to equity
0.1×
Beta
No index for this market yet

Medical devices & supplies: the 10 companies nearest in size, of 448 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Control Bionics Ltd. · ASX:CBLUS$15.13MUS$14.16Mn/a4.5×n/a3.6×−152.4%0.1×n/a
Modular Medical, Inc. · NASDAQ:MODDUS$16.36MUS$11.26Mn/an/an/a1.4×n/a0.0×2.27
European Medical Solutions. · EURONEXT:ALEMSUS$16.25MUS$33.71M8.1×0.6×6.3×1.1×3.7%1.5×n/a
Picard Medical, Inc. · AMEX:PMIUS$15.88MUS$17.30Mn/a3.3×n/a11.9×−371.7%1.1×0.41
SG Healthcare Co., Ltd. · KRX:398120US$15.78MUS$11.93M19.3×0.6×n/a0.9×4.2%0.0×n/a
Careplus Group Bhd. · MYX:CAREPLSUS$15.50MUS$20.64Mn/a0.8×n/a0.3×−11.1%0.1×n/a
HeartBeam, Inc. · NASDAQ:BEATUS$15.50MUS$9.44Mn/an/an/a2.4×n/a0.0×1.93
Lifecare ASA · OSL:LIFEUS$15.21MUS$11.43Mn/a175×n/a2.7×n/a0.0×n/a
Micro-X Ltd. · ASX:MX1US$14.45MUS$16.66Mn/a1.7×n/a4.5×−65.5%1.3×n/a
Perimeter Medical Imaging AI Inc · TSXV:PINKUS$14.45MUS$8.00Mn/a3.8×n/a3.5×−478.7%0.0×1.55
CVRx, Inc. · NASDAQ:CVRXUS$14.27MUS$14.18Mn/a0.2×n/a1.0×−88.3%4.2×1.28
Median of the othersUS$15.50MUS$13.06M13.7×1.2×6.3×1.9×−65.5%0.1×1.55

Team and board

Officers

OfficerRole
Jeremy SteeleChief Executive Officer
Shannon BoothroydChief Financial Officer
Todd TylerPresident, North America
Brett CrowleyCompany Secretary
Chris FeighnerDirector of Operations
James SchoreyChief Technical Officer
Jeffrey KitchenDirector of Product

Board

DirectorRole
Stephen RixChairman
Damian LismoreNon-Executive Director
Nicholas OpieNon-Executive Director
Rob HeardNon-Executive Director

Events

QuarterResultsShare move
Q2 2025Aug 28, 2025+2.7%
Q4 2024Feb 25, 2025−7.1%
Q4 2022Feb 23, 2023+6.2%
Q2 2022Aug 24, 2022 · Before open−1.0%
Q4 2021Feb 22, 2022 · After close−10.0%
Q2 2021Aug 25, 2021 · After close−2.8%
Q4 2020Feb 24, 2021 · After close0.0%

Open Events

Decks

DeckKindSlidesDate
Bell Potter Healthcare Conference 2026Conference7 slidesNov 18, 2026
Shareholder Meeting (October 2026)Shareholder meeting29 slidesOct 13, 2026
LSI Asia July 2026Conference12 slidesJul 1, 2026
Corporate Update (June 2026)Corporate update22 slidesJun 4, 2026
Investor Presentation (April 2026)Investor deck21 slidesMay 5, 2026
Investor Presentation (February 2026)Investor deck8 slidesFeb 26, 2026
Shareholder Meeting (November 2025)Shareholder meeting31 slidesNov 25, 2025
Investor Presentation (November 2025)Investor deck16 slidesNov 13, 2025
Coffee Microcaps Meeting (November 2024)Conference21 slidesNov 8, 2024
Shareholder Meeting (October 2024)Shareholder meeting22 slidesOct 10, 2024
All 25 decks
DeckKindSlidesDate
Investor Presentation (September 2024)Investor deck36 slidesSep 19, 2024
Techknow Conference 2024Conference13 slidesJul 31, 2024
United Nations AI for Good Summit (May 2024)Conference17 slidesMay 31, 2024
Investor Presentation (April 2024)Investor deck40 slidesApr 23, 2024
Shareholder Meeting (October 2023)Shareholder meeting27 slidesOct 10, 2023
Bioshares Biotech Summit (July 2023)Conference11 slidesJul 24, 2023
Investor Presentation (May 2023)Investor deck18 slidesMay 30, 2023
Investor Presentation (April 2023)Investor deck13 slidesApr 19, 2023
Shareholder Meeting (October 2022)Shareholder meeting30 slidesOct 6, 2022
Shareholder Meeting (October 2022)Shareholder meeting15 slidesOct 6, 2022
Morgans Technology Conference 2021Conference22 slidesNov 24, 2021
Investor Presentation (October 2021)Investor deck16 slidesOct 22, 2021
Shareholder Meeting (October 2021)Shareholder meeting34 slidesOct 13, 2021
H1 FY2021 Earnings PresentationEarnings24 slidesFeb 25, 2021
FY2016 Earnings PresentationEarnings33 slidesFeb 24, 2017

Open Decks

Financings

RaiseDateIn US dollars
Private placement of new ordinary shares
Announced: about A$9.5M · A$0.075 a share · Bell Potter Securities Limited +1
Dealers: Bell Potter Securities Limited (co-lead), Unified Capital Partners Pty Ltd (co-lead)
Buyers: Stephen Rix (2,040,000 shares, subject to shareholder approval); Jeremy Steele (1,160,000 shares, subject to shareholder approval); Nicholas Opie (400,000 shares, subject to shareholder approval); Robert Heard (333,333 shares, subject to shareholder approval); Damian Lismore (320,000 shares, subject to shareholder approval)
Insiders: Tranche 2 includes approximately 4.3 million shares (4,253,333) to directors, subject to shareholder approval
Use of proceeds: Commercialisation initiatives and working capital
Jun 25, 2026US$6.57M
Share purchase plan of new shares
Announced: up to A$500,000 · A$0.075 a share
Use of proceeds: Commercial expansion, platform and medtech development, strategic initiatives, working capital and offer costs
Jun 25, 2026US$345,572
Private placement of new fully paid ordinary shares
Announced: A$3.25M · A$0.065 a share
Buyers: Reitham Equity GmbH (anchored the placement)
Use of proceeds: Working capital to accelerate commercialisation of core assistive technology products and emerging neurotechnology markets
Dec 1, 2025US$2.13M

Open Financings · Read by 6ix AI from the company's releases

Financials

Annual, in AUD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue4.77M6.14M5.35M5.64M4.50M4.09M3.10M781.4K805.4K311.3M
Cost of revenue8.91M2.03M1.45M1.93M7.42M1.43M2.88M1.42M1.09M
Gross profit-4.14M4.11M3.90M3.71M-2.91M2.50M215.5K-634.1K-285.0K311.3M
Research and development1.24M1.07M1.71M231.0K328.9K166.2K68.3K361.2K79.0K
Selling, general and administrative6.44M1.54M5.67M5.29M4.91M3.33M786.3K137.9K71.8K30.3M
Operating income-7.29M-5.83M-5.93M-5.21M-6.01M-2.95M-1.20M-2.05M-1.06M54.9M
Depreciation and amortization792.5K986.5K843.2K480.4K507.9K198.5K115.2K9.22K4.71K6.32M
EBITDA-6.50M-4.84M-5.09M-4.73M-5.51M-2.75M-1.09M-2.04M-1.05M61.2M
Interest expense85.0K109.0K56.3K21.3K10.7K70.4K3.33K4361.16K13.4M
Income before tax-7.72M-6.11M-5.91M-5.63M-6.10M-3.55M-1.11M-2.05M-1.06M42.4M
Income tax-454.2K-426.6K-850.4K-412.8K-338.5K-116.3K-103.0K-114.9K-85.2K12.9M
Net income-7.27M-6.11M-5.91M-5.63M-6.11M-3.55M-1.01M-1.93M-972.5K28.6M
Earnings per share, basic-0.02-0.02-0.04-0.06-0.06-0.04-0.01-0.02-0.010.13

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents2.08M594.7K980.8K935.5K5.21M12.3M15.6M798.9K1.84M388.4M
Short-term investments77.9K77.9K56.2K56.2K13.1K7.32M
Receivables1.35M1.40M2.19M1.78M1.76M1.12M317.0K289.2K256.1K334.9M
Inventory451.6K409.6K404.1K801.9K924.0K269.4K179.0K180.5K88.0K
Current assets4.18M3.17M3.76M3.90M8.61M13.7M16.1M1.27M2.18M730.6M
Property, plant and equipment844.0K1.22M720.2K711.5K534.1K287.3K31.4K9.77K
Goodwill752.1K149.0M
Total assets9.05M8.23M9.03M8.70M13.4M18.4M20.5M5.43M6.31M1.16B
Accounts payable904.1K1.39M609.7K1.17M429.3K459.6K191.0K253.6K121.8K117.1K
Current liabilities2.72M2.55M2.40M1.56M1.36M1.17M364.0K375.8K215.9K13.0M
Long-term debt0235.7K
Total debt618.9K435.4K961.7K128.5K284.8K14.9K282.1K38.5M
Total liabilities2.73M2.72M2.76M1.58M1.51M1.19M387.0K375.8K215.9K876.4M
Shareholders' equity6.31M5.51M6.27M7.15M11.9M17.2M20.1M5.05M6.09M281.4M
Shares outstanding371.2M264.1M159.4M100.1M94.6M92.6M92.4M92.4M92.4M223.5M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-5.75M-4.27M-4.91M-4.53M-6.89M-3.99M-864.0K-1.95M-970.8K
Capital spending-10.0K-302.3K-473.1K-457.5K-147.7K-53.4K-301.8K-35.6K-14.3K-3.05M
Free cash flow-5.76M-4.57M-5.38M-4.98M-5.75M-4.04M-1.17M-1.98M-985.2K-3.05M
Cash from investing-269.8K-744.8K-473.1K-457.5K-147.7K-53.4K-301.8K-35.6K-14.3K54.6M
Cash from financing7.49M4.63M5.43M706.4K-87.3K14.9M1.79M933.4K2.63M54.6M
Dividends paid-48.5K-16.2M
Share buybacks-220.8K5.41M-114.5K862.8K14.1K-715.3K1.58M933.4K2.63M-4.15M
Change in cash1.48M-386.0K45.3K-4.28M-7.12M10.9M629.5K-1.04M1.65M103.7M

Open Financials

Filings

FilingDateTypeFiled with
Quarterly Activities/Appendix 4C Cash Flow ReportOct 28, 2026Quarterly reportASX
Quarterly Activities/Appendix 4C Cash Flow ReportOct 28, 2026Quarterly reportASX
Medicare Billing Code Secured for NextLevel Speech DevicesAug 26, 2026Operations updateASX
NeuroStrip secures MHRA registrationAug 24, 2026Operations updateASX
US FDA Registration and Device Listing for NeuroStripAug 3, 2026Operations updateASX
Commercial momentum builds across both platform pillarsJul 30, 2026Operations updateASX
Completion of PlacementJun 24, 2026FinancingASX
Pause in TradingJun 23, 2026Trading halt or suspensionASX
Commercial Momentum PresentationJun 3, 2026Operations updateASX
German Statutory Reimbursement Listing for NeuroNodeMar 3, 2026Operations updateASX
All 84 filings
FilingDateTypeFiled with
Joint venture with NextLevel Assistive TechnologyFeb 25, 2026Acquisition or disposalASX
Half Yearly Report and AccountsFeb 25, 2026Interim reportASX
PRC-Saltillo - Distribution AgreementJan 28, 2026Acquisition or disposalASX
Quarterly Activities/Appendix 4C Cash Flow ReportJan 27, 2026Quarterly reportASX
Tobii Dynavox - Distribution PartnershipJan 26, 2026Operations updateASX
Acquisition of Full Ownership of Neuro Elite AthleticsDec 2, 2025Acquisition or disposalASX
Placement to Raise $3.25 millionDec 1, 2025FinancingASX
Control Bionics Integrates with Apple BCI ProtocolNov 11, 2025Operations updateASX
Rights Issue Offer BookletSep 3, 2025Offer documentASX
Preliminary Final ReportAug 28, 2025ResultsASX
Non-Renounceable Rights IssueAug 27, 2025FinancingASX
FY25 Trading Update and NeuroStrip ProgressJun 12, 2025Other filingsASX
Private PlacementFeb 24, 2025FinancingASX
First Half FY25 Business UpdateDec 16, 2024ResultsASX
Expansion into US Sports and Japanese Rehab MarketsDec 15, 2024Operations updateASX
Coffee Microcaps Meeting PresentationNov 7, 2024Other filingsASX
SIGNIFICANT INCREASE IN REVENUE FROM FASTER NDIS APPROVALSOct 3, 2024ResultsASX
ADDENDUM TO NOTICE OF 2024 AGMSep 27, 2024Other filingsASX
PlacementSep 23, 2024FinancingASX
NON-RENOUNCEABLE RIGHTS ISSUE OFFER AND PRIVATE PLACEMENT ADSep 20, 2024FinancingASX
Non-Renounceable IssueSep 19, 2024Other filingsASX
Investor PresentationSep 19, 2024Other filingsASX
Trading HaltSep 19, 2024Trading halt or suspensionASX
Exclusive UK and Ireland Distribution AgreementSep 8, 2024Acquisition or disposalASX
New US Insurance Code ApprovedAug 18, 2024Operations updateASX
Share placement - North Star Impact Fund to investJul 31, 2024FinancingASX
TGA Approval Granted for DROVE Autonomous Wheelchair ModuleJun 19, 2024Operations updateASX
Control Bionics completes successful $1.04m placementMay 15, 2024FinancingASX
Autonomous Wheelchair Project - US Research AwardJan 23, 2024Operations updateASX
Completion of Placement of Rights Issue ShortfallJan 18, 2024FinancingASX
Rights Issue ResultsNov 29, 2023FinancingASX
Pro rata rights issueOct 29, 2023FinancingASX
Control Bionics Unveils the NeuroStripOct 12, 2023Other filingsASX
Extension to Rights Issue Closing DateJun 13, 2023FinancingASX
DROVE - Presentation at Deakin UniversityApr 18, 2023Other filingsASX
DROVE - Press ReleaseApr 18, 2023Other filingsASX
DROVE - Worlds First Wheelchair Self-drive ControllerApr 17, 2023Other filingsASX
Appointment of CEOJan 19, 2023Management or board changeASX
CEO ResignationSep 14, 2022Other filingsASX
Appendix 4EAug 24, 2022ResultsASX
Monthly Activities/Appendix 4C Cash Flow ReportApr 27, 2022Quarterly reportASX
CBL Enters Japanese Market with NeuroNode TechnologyApr 11, 2022Other filingsASX
Morgans Investment Conference PresentationNov 24, 2021Other filingsASX
Introduction of rental alternative to Australian marketOct 19, 2021Other filingsASX
Appendix 4C - QuarterlyApr 28, 2021Quarterly reportASX
Release of half year results and webinarFeb 22, 2021Interim reportASX
Appendix 4C - quarterlyJan 20, 2021Quarterly reportASX
Voluntary Administration Sale of PFP BusinessJul 4, 2018Other filingsASX
CBL Corporation enters Voluntary AdministrationFeb 25, 2018Other filingsASX
CBI DirectionFeb 19, 2018Other filingsASX
CBL updates the market on AM Best credit rating downgradeFeb 7, 2018Other filingsASX
Suspension from Official QuotationFeb 5, 2018Trading halt or suspensionASX
CBL UPDATES THE MARKET ON FY17 RESULTS EXPECTATIONSFeb 4, 2018Other filingsASX
CBL subsidiary in Luxembourg fined EUR5,000 being appealedJan 2, 2018Other filingsASX
Results Announcement - NZX Appendix 1Aug 23, 2017Other filingsASX
STRONG GROWTH BUT PROFIT IMPACTED BY STRENGTHENING RESERVESAug 17, 2017Operations updateASX
CBL ANNOUNCES IRISH ACQUISITIONJul 10, 2017Acquisition or disposalASX
CBL INSURANCE RETAINS RATING OF A-Jun 12, 2017Other filingsASX
CBL Share Sell-Down To Increase Share Market LiquidityApr 4, 2017Other filingsASX
CBL ANNOUNCES CONDITIONAL AGREEMENT TO BUY US INSURERMar 24, 2017Other filingsASX
CBL Supplementary Information for the 2016 Annual ResultFeb 28, 2017Other filingsASX
CBL Results PresentationFeb 23, 2017Other filingsASX
Focused and consistent strategy sees CBL beat forecastsFeb 23, 2017Other filingsASX
CBL CORPORATION CLOSES NZ$150M STRATEGIC ACQUISITIONJan 5, 2017Acquisition or disposalASX
CBL obtains regulatory approval for SFS AcquisitionOct 10, 2016Acquisition or disposalASX
CBL Corporation completes PlacementSep 29, 2016FinancingASX
CBL Corporation announces equity raisingSep 28, 2016Other filingsASX
CBL Corporation Limited 2016 Half Year ResultsAug 25, 2016Interim reportASX
CBL Corporation plans acquisition of SFSJun 22, 2016Acquisition or disposalASX
CBL announces maiden dividend.Mar 30, 2016DividendASX
Full Year Statutory AccountsFeb 28, 2016Annual reportASX
CBL ANNOUNCES NEW LICENCES IN MEXICOFeb 19, 2016Other filingsASX
CBL delivers clear strategy for Assetinsure Pty LtdFeb 11, 2016Other filingsASX
CBL exercises option to acquire shares from shareholderFeb 10, 2016Acquisition or disposalASX

Open Filings

Cap table

Built by 6ix from Control Bionics Ltd.’s releases · as of Jun 25, 2026

Common shares
544,132,796
Fully diluted
544,132,796

Fully diluted

LineShares
Common shares544,132,796

Share count over time

CountShares
Nov 22, 2026544,132,796

Open Cap table

Shareholders

TradeTradeSharesPriceValueDate
Jeremy Steele
Director
Buy399,859AUD 0.05AUD 21,214Nov 13, 2026
Stephen Rix
Director
Buy1,000,000AUD 0.05AUD 50,250Oct 29, 2026

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Brett CrowleyCompany Secretary · Since at least Nov 5, 2026
Chris FeighnerDirector of Operations · Since at least Nov 4, 2026
Damian LismoreNon-Executive Director · Since at least Nov 5, 2026
James SchoreyChief Technical Officer · Since at least Nov 4, 2026
Jeffrey KitchenDirector of Product · Since at least Nov 4, 2026
Jeremy SteeleChief Executive Officer · Since at least Nov 5, 2026
Nicholas OpieNon-Executive Director · Since at least Nov 5, 2026
Rob HeardNon-Executive Director · Since at least Nov 4, 2026
Shannon BoothroydChief Financial Officer · Since at least Nov 4, 2026
Stephen RixChairman · Since at least Nov 5, 2026
All 11 people
PersonSeat
Todd TylerPresident, North America · Since at least Nov 4, 2026

Open People

Log in to ask 6ix AI your own questions about Control Bionics Ltd.